Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)
Company Research
Source: Yahoo! Finance
approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial - - $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation - JERUSALEM, March 09, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® reported full year 2025 financial results and provided a corporate update. "The pace of progress at Alpha Tau today is unlike anything we've ever seen before," said Alpha Tau Chief Executive Officer Uzi Sofer. “With a slew of meaningful announcements
Show less
Read more
Impact Snapshot
Event Time:
DRTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRTS alerts
High impacting Alpha Tau Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
DRTS
News
- Alpha Tau Medical (DRTS) had its price target raised by Citigroup Inc. from $7.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Alpha Tau Medical (DRTS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Alpha Tau Medical GAAP EPS of -$0.42 [Seeking Alpha]Seeking Alpha
- Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Alpha Tau Medical (DRTS) had its "neutral" rating reaffirmed by Piper Sandler. They now have a $5.00 price target on the stock.MarketBeat
DRTS
Earnings
- 3/9/26 - Miss
DRTS
Sec Filings
- 3/9/26 - Form S-8
- 3/9/26 - Form 20-F
- 3/9/26 - Form 6-K
- DRTS's page on the SEC website